Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy.

Navari, Rudolph M; Rapoport, Bernardo L; Powers, Dan; Arora, Sujata; Clark-Snow, Rebecca

Navari, Rudolph M; Rapoport, Bernardo L; Powers, Dan; Arora, Sujata; Clark-Snow, Rebecca.

Afiliación

Navari RM; University of Alabama Birmingham School of Medicine, Birmingham, AL, USA.
Rapoport BL; Medical Oncology Centre of Rosebank, Johannesburg, South Africa.
Powers D; Department of Immunology, Faculty of Health Science, University of Pretoria, Pretoria, South Africa.
Arora S; TESARO, Inc., Waltham, MA, USA.
Clark-Snow R; TESARO, Inc., Waltham, MA, USA.

Cancer Med ; 7(7): 2943-2950, 2018 Jul.

Article en En | MEDLINE | ID: mdl-29790666

Palabras clave

anthracycline/cyclophosphamide; carboplatin; chemotherapy-induced nausea and vomiting; cisplatin; highly emetogenic chemotherapy; moderately emetogenic chemotherapy; nausea; neurokinin-1 receptor antagonist; rolapitant

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Cancer Med Año: 2018 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google